TheEdgeResearch
Home / Stocks / BRM.DE

Bristol-Myers Squibb Company (BRM.DE)

XETRA Healthcare Drug Manufacturers - General
$55.45 ▲ +0.33%
Market Cap
$113.27B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.23
52-Wk Range
36.6-61.19
CEO
Christopher S. Boerner
Country
US
Currency
EUR

Bristol-Myers Squibb Company operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Princeton, NY, US. The stock last traded at $55.45, up 0.33% on the session, giving a market capitalisation of $113.27B. Its beta of 0.23 implies it has historically moved less than the broad market.

Company profile
Exchange
Deutsche Börse
Employees
32,500
IPO date
1999-05-14
Headquarters
Princeton, NY, US
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates globally as a biopharmaceutical powerhouse, engaging in the research, development, licensing, manufacturing, and marketing of innovative health solutions. Its extensive product pipeline addresses critical conditions across various therapeutic areas, including hematology, oncology, cardiovascular health, immunology, fibrotic diseases, neuroscience, and COVID-19. Key offerings from the company include Revlimid, an oral immunomodulatory drug for treating multiple myeloma, and Eliquis, an oral inhibitor prescribed for reducing stroke risk in non-valvular atrial fibrillation and for managing deep vein thrombosis/pulmonary embolism. The anti-cancer therapy Opdivo is also part of its portfolio, alongside Pomalyst/Imnovid for multiple myeloma, and Orencia, used for adult patients with active rheumatoid arthritis and psoriatic arthritis. Other notable treatments comprise Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy product. Furthermore, the company provides Reblozyl for anemia in adult beta thalassemia patients, and Empliciti for multiple myeloma. More recent additions include Zeposia, targeting relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor for adult myelofibrosis; and Onureg, prescribed for adult acute myeloid leukemia. Bristol-Myers Squibb distributes its products through a wide network encompassing wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The firm, established in 1887 and formerly known as Bristol-Myers Company, is headquartered in New York, New York.

Comparable companies

Bristol-Myers Squibb Company is most often compared with the following Healthcare names:

CGN.DECVS.DEGIS.DEMRK.DEPFE.DEPFE.FSNW.DEVX1.DEZOE.DE
More research on BRM.DE
BRM.DE technical analysis BRM.DE TheEdge Score Compare against peers
Open full interactive analysis & DCF →